Investigating Codabakalner in a Phase 2b/3 Trial for the Treatment of Fragile X Syndrome: The CLARITY Study
Spinogenix’s codabakalner, an investigational BK channel modulator, is currently being evaluated in CLARITY, a phase 2b/3 trial for the treatment of patients with Fragile X syndrome.
Welcome to NeurologyLive's Clinical Trial in Focus. Every month, an ongoing clinical trial in the landscape of neurology is featured, highlighting the design of the study, the targeted patient population, the enrollment criteria, the primary and secondary end points, and its potential implications for clinical care. In honor of Fragile X Syndrome Awareness Day, held annually on July 22, this month’s spotlight is the phase 2b/3 CLARITY trial (NCT07439510) testing codabakalner (Spinogenix), formally known as SPG601, for the treatment of patients with Fragile X syndrome (FXS).1